Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By

57 Results

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Monday, 1/24/2022

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 01/24/2022 at 8:00 PM (EST)

    This is PART 1 of the waiver eligibility training. NOTE: This training has a starting time of 5:00 pm Pacific Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    This is PART 1 of the 8-hour waiver eligibility training.
    NOTE: This training has a starting time of 5:00 pm Pacific Time Zone. Please check your time zone for start time. Please download the Zoom app prior to training. https://zoom.us/ent?zcid=2582

    Physicians are required to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. Those physicians who want to treat more than 30 patients at any one time, must take the 8-hour waiver course.

    To treat more than 30 patients, Advanced Practice Registered Nurses (APRN) (NP/CNM/CNS/CRNA) and Physician Assistants (PAs) must complete 24 hours of specialized training to prescribe buprenorphine. The training includes 8 hours of waiver training and an additional 16 hours of training.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session.
    Instructions on how to log on to Part 2 of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please allow up to 48 hours to receive the email. It is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions and case studies in order for the AOAAM to verify your attendance. PHONE ONLY PARTICIPATION DOES NOT QUALIFY FOR PARTICIPATION CREDIT.


    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Stephen A. Wyatt, DO

    Medical Director, Addiction Medicine Carolinas HealthCare System Charlotte, NC

    Dr. Wyatt is a graduate Chicago College of Osteopathic Medicine. He practiced Emergency Medicine in Michigan for 13 years before entering a psychiatric residency at University Hospitals of Cleveland, Case Western Reserve University in 1993.  He then entered a NIDA Clinical Research Fellowship in the Yale School of Medicine in Addiction Psychiatry. His primary interest and research has been in co-morbid problems, adolescents, and education.  He sits on a variety of Federal committees on substance use disorders including the Physician Clinical Support System, PCSS, for Medication Assisted Treatment.  He served on the expert panel for office based use of Buprenorphine for the Federation of State Medical Boards. He is the Past President of the Connecticut Society of Addiction Medicine and the American Osteopathic Academy of Addiction Medicine. He was a Board Co-chair for the Connecticut Department of Mental Health and Addiction Services   He has been active in all levels of medical education in advocating for greater understanding and improvement in treatment of substance use problems in the provision of care.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Saturday, 1/8/2022

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 01/08/2022 at 8:00 AM (EST)

    This is PART 1 of the waiver eligibility training. NOTE: This training has a starting time of 8:00 am Eastern Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    This is PART 1 of the 8-hour waiver eligibility training.
    NOTE: This training has a starting time of 8:00 am Eastern Time Zone. Please check your time zone for start time. Please download the Zoom app prior to training. https://zoom.us/ent?zcid=2582

    Physicians are required to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. Those physicians who want to treat more than 30 patients at any one time, must take the 8-hour waiver course.

    To treat more than 30 patients, Advanced Practice Registered Nurses (APRN) (NP/CNM/CNS/CRNA) and Physician Assistants (PAs) must complete 24 hours of specialized training to prescribe buprenorphine. The training includes 8 hours of waiver training and an additional 16 hours of training.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session.
    Instructions on how to log on to Part 2 of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please allow up to 48 hours to receive the email. It is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions and case studies in order for the AOAAM to verify your attendance. PHONE ONLY PARTICIPATION DOES NOT QUALIFY FOR PARTICIPATION CREDIT.


    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Stephen A. Wyatt, DO

    Medical Director, Addiction Medicine Carolinas HealthCare System Charlotte, NC

    Dr. Wyatt is a graduate Chicago College of Osteopathic Medicine. He practiced Emergency Medicine in Michigan for 13 years before entering a psychiatric residency at University Hospitals of Cleveland, Case Western Reserve University in 1993.  He then entered a NIDA Clinical Research Fellowship in the Yale School of Medicine in Addiction Psychiatry. His primary interest and research has been in co-morbid problems, adolescents, and education.  He sits on a variety of Federal committees on substance use disorders including the Physician Clinical Support System, PCSS, for Medication Assisted Treatment.  He served on the expert panel for office based use of Buprenorphine for the Federation of State Medical Boards. He is the Past President of the Connecticut Society of Addiction Medicine and the American Osteopathic Academy of Addiction Medicine. He was a Board Co-chair for the Connecticut Department of Mental Health and Addiction Services   He has been active in all levels of medical education in advocating for greater understanding and improvement in treatment of substance use problems in the provision of care.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Monday, 12/27/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 12/27/2021 at 8:00 PM (EST)

    This is PART 1 of the waiver eligibility training. NOTE: This training has a starting time of 5:00 pm Pacific Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    This is PART 1 of the 8-hour waiver eligibility training.
    NOTE: This training has a starting time of 5:00 pm Pacific Time Zone. Please check your time zone for start time. Please download the Zoom app prior to training. https://zoom.us/ent?zcid=2582

    Physicians are required to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. Those physicians who want to treat more than 30 patients at any one time, must take the 8-hour waiver course.

    To treat more than 30 patients, Advanced Practice Registered Nurses (APRN) (NP/CNM/CNS/CRNA) and Physician Assistants (PAs) must complete 24 hours of specialized training to prescribe buprenorphine. The training includes 8 hours of waiver training and an additional 16 hours of training.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session.
    Instructions on how to log on to Part 2 of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please allow up to 48 hours to receive the email. It is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions and case studies in order for the AOAAM to verify your attendance. PHONE ONLY PARTICIPATION DOES NOT QUALIFY FOR PARTICIPATION CREDIT.


    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Stephen A. Wyatt, DO

    Medical Director, Addiction Medicine Carolinas HealthCare System Charlotte, NC

    Dr. Wyatt is a graduate Chicago College of Osteopathic Medicine. He practiced Emergency Medicine in Michigan for 13 years before entering a psychiatric residency at University Hospitals of Cleveland, Case Western Reserve University in 1993.  He then entered a NIDA Clinical Research Fellowship in the Yale School of Medicine in Addiction Psychiatry. His primary interest and research has been in co-morbid problems, adolescents, and education.  He sits on a variety of Federal committees on substance use disorders including the Physician Clinical Support System, PCSS, for Medication Assisted Treatment.  He served on the expert panel for office based use of Buprenorphine for the Federation of State Medical Boards. He is the Past President of the Connecticut Society of Addiction Medicine and the American Osteopathic Academy of Addiction Medicine. He was a Board Co-chair for the Connecticut Department of Mental Health and Addiction Services   He has been active in all levels of medical education in advocating for greater understanding and improvement in treatment of substance use problems in the provision of care.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Monday, 11/22/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 11/22/2021 at 8:00 PM (EST)

    This is PART 1 of the waiver eligibility training. NOTE: This training has a starting time of 5:00 pm Pacific Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    This is PART 1 of the 8-hour waiver eligibility training.
    NOTE: This training has a starting time of 5:00 pm Pacific Time Zone. Please check your time zone for start time. Please download the Zoom app prior to training. https://zoom.us/ent?zcid=2582

    Physicians are required to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. Those physicians who want to treat more than 30 patients at any one time, must take the 8-hour waiver course.

    To treat more than 30 patients, Advanced Practice Registered Nurses (APRN) (NP/CNM/CNS/CRNA) and Physician Assistants (PAs) must complete 24 hours of specialized training to prescribe buprenorphine. The training includes 8 hours of waiver training and an additional 16 hours of training.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session.
    Instructions on how to log on to Part 2 of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please allow up to 48 hours to receive the email. It is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions and case studies in order for the AOAAM to verify your attendance. PHONE ONLY PARTICIPATION DOES NOT QUALIFY FOR PARTICIPATION CREDIT.


    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Stephen A. Wyatt, DO

    Medical Director, Addiction Medicine Carolinas HealthCare System Charlotte, NC

    Dr. Wyatt is a graduate Chicago College of Osteopathic Medicine. He practiced Emergency Medicine in Michigan for 13 years before entering a psychiatric residency at University Hospitals of Cleveland, Case Western Reserve University in 1993.  He then entered a NIDA Clinical Research Fellowship in the Yale School of Medicine in Addiction Psychiatry. His primary interest and research has been in co-morbid problems, adolescents, and education.  He sits on a variety of Federal committees on substance use disorders including the Physician Clinical Support System, PCSS, for Medication Assisted Treatment.  He served on the expert panel for office based use of Buprenorphine for the Federation of State Medical Boards. He is the Past President of the Connecticut Society of Addiction Medicine and the American Osteopathic Academy of Addiction Medicine. He was a Board Co-chair for the Connecticut Department of Mental Health and Addiction Services   He has been active in all levels of medical education in advocating for greater understanding and improvement in treatment of substance use problems in the provision of care.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Saturday, 11/6/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 11/06/2021 at 10:00 AM (EDT)

    This is PART 1 of the waiver eligibility training. NOTE: This training has a starting time of 10:00 am Eastern Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    This is PART 1 of the 8-hour waiver eligibility training.
    NOTE: This training has a starting time of 10:00 am Eastern Time Zone. Please check your time zone for start time. Please download the Zoom app prior to training. https://zoom.us/ent?zcid=2582

    Physicians are required to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. Those physicians who want to treat more than 30 patients at any one time, must take the 8-hour waiver course.

    To treat more than 30 patients, Advanced Practice Registered Nurses (APRN) (NP/CNM/CNS/CRNA) and Physician Assistants (PAs) must complete 24 hours of specialized training to prescribe buprenorphine. The training includes 8 hours of waiver training and an additional 16 hours of training.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session.
    Instructions on how to log on to Part 2 of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please allow up to 48 hours to receive the email. It is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions and case studies in order for the AOAAM to verify your attendance. PHONE ONLY PARTICIPATION DOES NOT QUALIFY FOR PARTICIPATION CREDIT.


    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Stephen A. Wyatt, DO

    Medical Director, Addiction Medicine Carolinas HealthCare System Charlotte, NC

    Dr. Wyatt is a graduate Chicago College of Osteopathic Medicine. He practiced Emergency Medicine in Michigan for 13 years before entering a psychiatric residency at University Hospitals of Cleveland, Case Western Reserve University in 1993.  He then entered a NIDA Clinical Research Fellowship in the Yale School of Medicine in Addiction Psychiatry. His primary interest and research has been in co-morbid problems, adolescents, and education.  He sits on a variety of Federal committees on substance use disorders including the Physician Clinical Support System, PCSS, for Medication Assisted Treatment.  He served on the expert panel for office based use of Buprenorphine for the Federation of State Medical Boards. He is the Past President of the Connecticut Society of Addiction Medicine and the American Osteopathic Academy of Addiction Medicine. He was a Board Co-chair for the Connecticut Department of Mental Health and Addiction Services   He has been active in all levels of medical education in advocating for greater understanding and improvement in treatment of substance use problems in the provision of care.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Saturday, 10/9/2021

    Contains 6 Component(s), Includes Credits Includes a Live Web Event on 10/09/2021 at 8:00 AM (EDT)

    This is PART 1 of the waiver eligibility training. NOTE: This training has a starting time of 8:00 am Eastern Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

    This is PART 1 of the 8-hour waiver eligibility training.
    NOTE: This training has a starting time of 8:00 am Eastern Time Zone. Please check your time zone for start time. Please download the Zoom app prior to training. https://zoom.us/ent?zcid=2582

    Physicians are required to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. Those physicians who want to treat more than 30 patients at any one time, must take the 8-hour waiver course.

    To treat more than 30 patients, Advanced Practice Registered Nurses (APRN) (NP/CNM/CNS/CRNA) and Physician Assistants (PAs) must complete 24 hours of specialized training to prescribe buprenorphine. The training includes 8 hours of waiver training and an additional 16 hours of training.

    The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session.
    Instructions on how to log on to Part 2 of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please allow up to 48 hours to receive the email. It is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions and case studies in order for the AOAAM to verify your attendance. PHONE ONLY PARTICIPATION DOES NOT QUALIFY FOR PARTICIPATION CREDIT.


    CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

    For More Information and FREE training and educational resources visit: www.pcssnow.org.

    Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

    Stephen A. Wyatt, DO

    Medical Director, Addiction Medicine Carolinas HealthCare System Charlotte, NC

    Dr. Wyatt is a graduate Chicago College of Osteopathic Medicine. He practiced Emergency Medicine in Michigan for 13 years before entering a psychiatric residency at University Hospitals of Cleveland, Case Western Reserve University in 1993.  He then entered a NIDA Clinical Research Fellowship in the Yale School of Medicine in Addiction Psychiatry. His primary interest and research has been in co-morbid problems, adolescents, and education.  He sits on a variety of Federal committees on substance use disorders including the Physician Clinical Support System, PCSS, for Medication Assisted Treatment.  He served on the expert panel for office based use of Buprenorphine for the Federation of State Medical Boards. He is the Past President of the Connecticut Society of Addiction Medicine and the American Osteopathic Academy of Addiction Medicine. He was a Board Co-chair for the Connecticut Department of Mental Health and Addiction Services   He has been active in all levels of medical education in advocating for greater understanding and improvement in treatment of substance use problems in the provision of care.

    This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

    CME certificates will be provided 30 days after the training date.

  • AMMP - Addiction Medicine Mentorship Program 2021-22

    Contains 8 Component(s) Includes Multiple Live Events. The next is on 10/06/2021 at 6:00 PM (EDT) Recorded On: 09/01/2021

    This longitudinal, year-long program (May 2021-May 2022) will offer medical students (MS1-MS4) an opportunity to engage with experts in the field of addiction while working towards the completion of a research project. This opportunity offers interested medical students an opportunity to engage with the clinical and academic aspects of addiction treatment and research. This program will provide the tools to treat patients with Substance Use Disorders in whichever field or specialty you ultimately pursue.

    This longitudinal, year-long program (May 2021-May 2022) will offer medical students (MS1-MS4) an opportunity to engage with experts in the field of addiction while working towards the completion of a research project. 

    This opportunity offers interested medical students an opportunity to engage with the clinical and academic aspects of addiction treatment and research. This program will provide the tools to treat patients with Substance Use Disorders in whichever field or specialty you ultimately pursue.

    Schedule:

    Please watch "The Hungry Heart" prior to 6/3/21.  https://vimeo.com/ondemand/the...

    Dr. Kushner has asked that all mentees view the documentary film "The Hungry Heart" prior to her talk. It's about 90 minutes, and can be rented on Vimeo for $3.99. This should be the only time we ask mentees to spend any money on this program, but if you have issues/questions/concerns, please reach out to Dr. Latronica and we can find an arrangement. She also asked me to mention that some of the language in the documentary (specifically stigmatizing language) likely does not "hold up" in our current environment, but she believes the documentary as a whole is important viewing.

    TimeSpeakerMeeting 1: Introduction (6/3/21)
    6:00-8:00  Marla Kushner, D.O."Addiction 101"
    Short Break   
    8:00-9:00 Whole Group Intro Session

    TimeSpeakerMeeting 2: Harm Reduction (8/3/21)
    6:00-7:00Elizabeth Salisbury-Afshar, M.D.Basics of Harm Reduction 
    Short Break  
    7:00-8:00 Mentorship Breakout Groups
    8:00-8:10 Whole Group Wrap-Up
    TimeSpeakerMeeting 3: Special Considerations in Addiction Medicine (9/1/21)
    6:00-7:00Veronica Ridpath, D.O.Taking a Compassionate Substance Use History
    Short Break  
    7:00-8:00 Mentorship Breakout Groups
    8:00-8:10 Whole Group Wrap-Up
    TimeSpeakerMeeting 4: Opioid Use Disorder (10/6/21)
    6:00-7:00Katherine Grieco, D.O.Epidemiology, Diagnosis, and Treatment
    Short Break
     
    7:00-8:00 Mentorship Breakout Groups
    8:00-8:10 Whole Group Wrap-Up
    TimeSpeakerMeeting 5: Alcohol Use Disorder (11/3/21)
    6:00-7:00Jon Lepley, D.O.Epidemiology, Diagnosis, and Treatment
    Short Break  
    7:00-8:00 Mentorship Breakout Groups
    8:00-8:10 Whole Group Wrap-Up
    TimeSpeakerMeeting 6: Stimulant Use Disorder (12/1/21)
    6:00-7:00James Latronica, D.O.Epidemiology, Diagnosis, and Treatment
    Short Break  
    7:00-8:00 Mentorship Breakout Groups
    8:00-8:10 Whole Group Wrap-Up
    TimeSpeakerMeeting 7:  Sedative/Hypnotic Use Disorder(2/2/22)
    6:00-7:00Steve Wyatt, D.O.Epidemiology, Diagnosis, and Treatment
    Short Break  
    7:00-8:00 Mentorship Breakout Groups
    8:00-8:10 Whole Group Wrap-Up
    TimeSpeakerMeeting 8: Behavioral Addictions & Project Wrap-Up (3/2/22)
    6:00-7:00Bhavna Bali, M.D.Epidemiology, Diagnosis, and Treatment
    Short Break  
    7:00-8:00 Independent Project Presentations
    8:00-8:10  


    Student Mentors:

    • Kelly Arnez, DO
    • William Bograkos, DO
    • Anthony Dekker, DO
    • Michael Fox, DO
    • R. Gregory Lande, DO
      Michael Steelman, DO
    • Jan Widerman, DO


      James Latronica, DO (Moderator)

      AOAAM Board of Trustee

      Program Moderator
      Speaker - December 1, 2021

      James R. Latronica, DO received his medical degree from the Philadelphia College of Osteopathic Medicine. His primary training is in Family Medicine, and he graduated residency from Clarion Hospital, in Clarion, PA. He is currently an Addiction Medicine Fellow at Penn State Hershey Medical Center. He is a past Resident Member of the AOAAM Board of Trustees, and he is honored to now serve as a full member.

      His main areas of academic interest are buprenorphine management in the perioperative period, expanded access to MOUD across all demographics, cannabis research, and U.S. drug and health care policy. He is the Associate Editor the Journal of Addictive Diseases.

      He has a deep interest in activism and advocacy and is a member of the American Society of Addiction Medicine’s Public Policy Committee. He also completed the American Osteopathic Association’s Training In Policy Studies (TIPS) Fellowship. In a non-academic role, he was a Pennsylvania field manager for Vot-ER, a physician-driven voter registration campaign during the 2020 presidential campaign. Three of his policy resolutions have been considered by the AOA House of Delegates, one of which was passed at the 2020 House of Delegates.

      He has significant investment in medical education at various levels, and to that end, he is a member of the Pennsylvania Osteopathic Medical Association’s Grant Development Task Force, he received the Philadelphia College of Osteopathic Medicine’s “PCOM Pillar” recognition for his mentorship activities with medical students, and was a past recipient of the Resident Teacher Award from the Society for Teachers of Family Medicine.

      Summer of 2021 he will be joining UPMC Western Psychiatric Hospital in a clinical role, and the University of Pittsburgh School of Medicine as an Assistant Professor.

      Marla Kushner, DO, FAOAAM

      AOAAM President

      Speaker - June 3, 2021

      Doctor Marla Kushner graduated from the Michigan State University College of Osteopathic Medicine. She completed her family medicine residency at Botsford General Hospital in Farmington Hills, MI and completed an Adolescent Young Adult Medicine Fellowship at Chicago Osteopathic Hospital of Rush Presbyterian St. Luke's Hospital in Chicago. After her fellowship, Dr. Kushner began working with adolescent substance abuse facilities in Chicago and received certification and Addiction Medicine from the American Society of Addiction Medicine and is a distinguished fellow of ASAM. She is a diplomate in American Board of Addiction Medicine. Dr. Kushner received her fellowship in the American College of Osteopathic Family Physicians in March 2013 and is currently medical director of the Addiction Recovery Track at Insight Behavioral Health in Chicago and  two high school-based health centers in Chicago. She has a family medicine practice with a focus on adolescent an addiction medicine. 

      Elizabeth Salisbury-Afshar

      Speaker - August 3, 2021

      Dr. Salisbury-Afshar’s focus is on improving the health and wellbeing of people who use drugs and alcohol. Her work includes individual patient care, clinical teaching, and implementation and evaluation of addiction-related programs. She is board certified in family medicine, addiction medicine, and preventive medicine/general public health.

      Prior to coming to the University of Wisconsin, Dr. Salisbury-Afshar has worked in the public and not for profit sectors. She served as the Medical Director of Behavioral Health Systems Baltimore, where she developed and oversaw the Baltimore City Overdose Prevention Plan, the Opioid Fatality Review Board, and the third-party naloxone distribution program. She subsequently served as the Medical Director of Behavioral Health at the Chicago Department of Public Health, where she created and implemented the Department’s strategy to address the opioid overdose crisis, helped to standardize the way opioid-related morbidity and mortality was tracked and reported, developed provider education learning collaboratives to increase access to medications for opioid use disorder (MOUD) treatment, and supported expansion of naloxone access through funding and educational initiatives. Dr. Salisbury-Afshar also served as the Director of the Center for Addiction Research and Effective Solutions (CARES) at the American Institutes for Research. In this role she worked on a variety of projects ranging from addiction-related public health strategy to the development of technical assistance to expand access to evidence-based addiction treatment.

      Dr. Salisbury-Afshar has over ten years of experience working clinically in federally qualified health centers- providing both primary care and addiction medicine treatment. She currently practices at Access Community Health Centers and as a consulting physician in addiction medicine at UW Hospital. She is Faculty in the UW Addiction Medicine Fellowship Program.

      Veronica Ridpath, DO

      AOAAM Resident - Board of Trustee

      Speaker - September 1, 2021

      My professional interests include community psychiatry, addiction psychiatry, and patient advocacy. I also have a special interest in working with LGBT, alternative, and diverse client populations. Currently serving as the Atrium Health Psychiatry Resident Representative to the NCPA Executive Council as well as Addiction Committee member.

      Katherine Grieco

      Speaker - October 6, 2021

      Dr Katherine Grieco graduated from the University of New England College of Osteopathic Medicine in Biddeford, Maine. She completed her residency in family medicine at St. Joseph Medical Center (now part of Penn State Health) in Reading, PA.  After residency she completed an HIV primary care fellowship at The University of California –San Francisco, followed by an addiction medicine fellowship at Yale School of Medicine. She is the former medical director of South Central Rehabilitation Center in New Haven which houses a detoxification center, methadone maintenance treatment program and an outpatient buprenorphine clinic. She most recently served as the medical director of HAVEN (Health Assistance Intervention & Education Network), the health and wellness monitoring program for healthcare professionals in the state of Connecticut who are facing issues related to substance use, and/or mental health. 

       Currently Dr. Grieco is employed by Hartford Healthcare in Connecticut where she treats patients in a withdrawal management unit, as well as in the MATCH program (Medication Assisted Treatment Closer to Home), an intensive outpatient program for patients with substance use/mental health concerns. She also does addiction medicine consultations for patients with HIV within the Hartford Healthcare Community Care Clinic. Dr. Grieco is dually board-certified in family medicine from the American Osteopathic Board of Family Physicians, and in addiction medicine from the American Board of Preventive Medicine. She is a fellow of the American Society of Addiction Medicine. 

      Jon Lepley, DO

      AOAAM President Elect

      Speaker - November 3, 2021

      Jon Lepley, DO received his medical degree from Lake Erie College of Osteopathic Medicine and he completed his Family Medicine residency training at Heart of Lancaster Regional Medical Center. He is Board Certified by the American Osteopathic Board of Family Physicians, with a Certificate of Added Qualifications in Addiction Medicine. He is a Diplomate of the American Board of Addiction Medicine and he is recognized as a Certified Correctional Health Professional by the National Commission on Correctional Health Care. He has been conferred Fellow status by the American Society of Addiction Medicine.

      Dr. Lepley spent many formative years of practice providing healthcare within the Philadelphia Department of Prisons, wherein he pioneered a program which provides Medication Assisted Treatment to individuals suffering from opioid use disorder. His work in Philadelphia has been recognized by the College of Physicians of Philadelphia Section of Public Health and his program has been presented on a national level, garnering interest from large correctional systems across the country. Dr. Lepley’s clinical interests also include recognition of physician impairment and promotion of physician wellness. In this regard, he volunteers his time to serve on an Advisory Committee for the Pennsylvania Physician Health Program. His current professional role is with Penn Medicine as Medical Director of Addiction Medicine for the Lancaster General Health system.

       

      Stephen Wyatt, DO, FAOAAM

      AOAAM Past President

      Steven Wyatt is a Board Certified Psychiatrist with added subspecialty certification in Addiction Psychiatry. He Completed a NIDA clinical research fellowship in addiction psychiatry at Yale School of Medicine. He is a CHS professor of psychiatry and an adjunct clinical faculty member of the University of North Carolina. He is the current chairman of the NC psychiatric Association Addiction Psychiatry Committee and the Vice Chair of the Coalition of Physician Education and Substance Use Disorders a national organization focused on addiction medicine medical school education. He participated in the writing of the ASAM Clinical Guidelines for Office Based Opioid Treatment. He is a clinical expert for both that UNC ECHO for Rural Primary Care MAT in North Carolina and the SAMHSA funded Provider Clinical Support System, PCSS; MAT and MIP projects. 

      Bhavna Bali

      Speaker - March 2, 2022

      Bhavna Bali, MD is an Assistant Professor of Internal Medicine and an Addiction Medicine Specialist at Penn State Health Milton S. Hershey Medical Center. She completed primary training in Internal Medicine at Piedmont Athens Regional Hospital in Athens, Georgia with a prime focus in Primary Care, and then completed her Addiction Medicine Fellowship at Penn State. She received her medical degree (MBBS-Bachelor of Medicine and Bachelor of Surgery) from Government Medical College of Patiala in Punjab, India.

      Her main academic interests are focused on expanding patient access to high quality care and evidence-based medications for substance use disorders across all populations. She has a special interest in quality improvement projects focusing on improving health system protocols in both inpatient and outpatient settings. Her passion is to promote and implement harm reduction methods and to continue working on reducing the stigmas healthcare professionals, society, and patients may have when it comes to substance use disorders. She enjoys teaching and taking part in the education of medical students and residents.

      Dr. Bali remains a member of the American Society of Addiction Medicine and American College of Physicians. She also recently became a member of Vot-ER group, which is a Physician driven voter registration campaign, and is currently completing a Civic Health Fellowship with them.  Outside of medicine Bhavna enjoys dancing, painting, and spending time with her family.

    • PCSS Office-Based Treatment for Opioid Use Disorders Webinar - Monday, 9/27/2021

      Contains 6 Component(s), Includes Credits Includes a Live Web Event on 09/27/2021 at 8:00 PM (EDT)

      This is PART 1 of the waiver eligibility training. NOTE: This training has a starting time of 5:00 pm Pacific Time Zone! For questions please contact Lara Renucci at: pcssmat@aoaam.org

      This is PART 1 of the 8-hour waiver eligibility training.
      NOTE: This training has a starting time of 5:00 pm Pacific Time Zone. Please check your time zone for start time. Please download the Zoom app prior to training. https://zoom.us/ent?zcid=2582

      Physicians are required to apply to the Drug Enforcement Agency for a waiver to prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder. Those physicians who want to treat more than 30 patients at any one time, must take the 8-hour waiver course.

      To treat more than 30 patients, Advanced Practice Registered Nurses (APRN) (NP/CNM/CNS/CRNA) and Physician Assistants (PAs) must complete 24 hours of specialized training to prescribe buprenorphine. The training includes 8 hours of waiver training and an additional 16 hours of training.

      The first half of the training is a 4.25-hour live webcast. The second half of the course is a 3.75-hour computer-based study. An examination on the computer study must be successfully completed within 30 days of the webinar session.
      Instructions on how to log on to Part 2 of the course will be provided via email, ONLY to those who complete the 4.25-hour live webcast in its entirety. Please allow up to 48 hours to receive the email. It is MANDATORY that you are able to view and hear the presentation and participate in the interactive polling questions and case studies in order for the AOAAM to verify your attendance. PHONE ONLY PARTICIPATION DOES NOT QUALIFY FOR PARTICIPATION CREDIT.


      CONTINUING MEDICAL EDUCATION: This session has been approved for 4.25 AOA Category 1-A CME credits, providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit. CME certificates will become available once all components of the training are fulfilled.

      For More Information and FREE training and educational resources visit: www.pcssnow.org.

      Funding for this initiative was made possible (in part) by grant no. 1H79TI081968 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

      Stephen A. Wyatt, DO

      Medical Director, Addiction Medicine Carolinas HealthCare System Charlotte, NC

      Dr. Wyatt is a graduate Chicago College of Osteopathic Medicine. He practiced Emergency Medicine in Michigan for 13 years before entering a psychiatric residency at University Hospitals of Cleveland, Case Western Reserve University in 1993.  He then entered a NIDA Clinical Research Fellowship in the Yale School of Medicine in Addiction Psychiatry. His primary interest and research has been in co-morbid problems, adolescents, and education.  He sits on a variety of Federal committees on substance use disorders including the Physician Clinical Support System, PCSS, for Medication Assisted Treatment.  He served on the expert panel for office based use of Buprenorphine for the Federation of State Medical Boards. He is the Past President of the Connecticut Society of Addiction Medicine and the American Osteopathic Academy of Addiction Medicine. He was a Board Co-chair for the Connecticut Department of Mental Health and Addiction Services   He has been active in all levels of medical education in advocating for greater understanding and improvement in treatment of substance use problems in the provision of care.

      This program has been approved for 4.25 AOA Category 1-A CME credits (live webcast session only) providing all requirements have been met. It has also been approved for 4.25 AAFP Prescribed Credit hours, which are eligible for the AMA’s Physician Recognition Award Credit. Participants are required to attend the entire 4.25-hour session, participate in the interactive polling questions and complete the post-test with a passing grade of 70% in order to be eligible for CME credit.

      CME certificates will be provided 30 days after the training date.

    • ORN Webinar Fall 2021 #6 - Case Studies and Q&A: Treating Opioid Use Disorder in Pregnancy and the Perinatal Period

      Contains 3 Component(s), Includes Credits Includes a Live Web Event on 09/22/2021 at 5:00 PM (EDT)

      (Part 2) ORN Webinar Series: A two-part, one hour each, webinar on treating opioid use disorder in pregnancy and the perinatal period. The second hour will be devoted to Q&A. Case studies may be included in the Q&A session to advance ones knowledge on the topic. If you have not registered for one of our webinars in the past, please subscribe to AOAAM (https://aoaam.org/subscribe), then login and register for the webinars. This webinar has been approved for a maximum 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

      (Part 2) ORN Webinar Series: A two-part, one hour each, webinar on treating opioid use disorder in pregnancy and the perinatal period. The second hour will be devoted to Q&A. Case studies may be included in the Q&A session to advance ones knowledge on the topic.

      If you have not registered for one of our webinars in the past, please subscribe to AOAAM, then login and register for the webinars.

      Goals & Objectives: 

      1. TBA

      Needs Assessment: 

      TBA

      This webinar series has been approved for a maximum 6, AOA Category 1-A CME credits, and AOA designates this for a maximum of 6, AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

      Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

      Davida Schiff, MD

      MassGeneral for Children

      Dr. Schiff is a general academic pediatrician and health services researcher focused on understanding how substance use in pregnant and parenting women impacts the health of children and families. She is the Medical Director of the HOPE Clinic (Harnessing support for Opioid and substance use disorder in Pregnancy and Early childhood) at Massachusetts General Hospital, a multidisciplinary program caring for women and families with substance use disorder from the time of conception through the first two years postpartum.

      Dr. Schiff completed her undergraduate training at Columbia University, medical training at the Boston University School of Medicine, pediatrics residency in the Boston Combined Residency Program at Boston Medical Center and Boston Children’s Hospital, general pediatrics research fellowship at Boston Medical Center, and master’s program in health services research from the Boston University School of Public Health. Her research is focused on improving care for families affected by substance use and her past scholarship has been published in the New England Journal of Medicine, JAMA, Pediatrics, Academic Pediatrics, Journal of Substance Abuse and Treatment, and Substance Abuse, among other journals. She is an Assistant Professor of pediatrics at Harvard Medical School.

      Julie Kmiec, DO, FAOAAM (Moderator)

      AOAAM Past President

      Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.

    • ORN Webinar Fall 2021 #5 - Treating Opioid Use Disorder in Pregnancy and the Perinatal Period

      Contains 3 Component(s), Includes Credits Recorded On: 09/15/2021

      (Part 1) ORN Webinar Series: A two-part, one hour each, webinar on treating opioid use disorder in pregnancy and the perinatal period. The second hour will be devoted to Q&A. Case studies may be included in the Q&A session to advance ones knowledge on the topic. If you have not registered for one of our webinars in the past, please subscribe to AOAAM (https://aoaam.org/subscribe), then login and register for the webinars. This webinar has been approved for a maximum 1 AOA Category 1-A CME credits, and AOA designates this for a maximum of 1 AMA PRA Category 1 Credits™.

      (Part 1) ORN Webinar Series: A two-part, one hour each, webinar on treating opioid use disorder in pregnancy and the perinatal period. This lecture will discuss care of pregnant and postpartum people with Opioid Use Disorder and their families and discuss and debunk common myths and misperceptions. The second hour will be devoted to Q&A. Case studies may be included in the Q&A session to advance ones knowledge on the topic.

      If you have not registered for one of our webinars in the past, please subscribe to AOAAM, then login and register for the webinars.

      Goals & Objectives: 

      1. Review limitations and biases in presenting existing national prevalence data in perinatal opioid use
      2. Describe treatment considerations for women with OUD during pregnancy Explore the unique stigma and discrimination surrounding pregnancy and SUD treatment
      3. Identify opportunities for improved engagement, care, and collaboration in preparation for delivery. 
      4. Discuss the unique risks to substance-exposed families in the early postpartum period, including recurrence of substance use

      This webinar series has been approved for a maximum 6, AOA Category 1-A CME credits, and AOA designates this for a maximum of 6, AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of the extent of their participation. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Osteopathic Association (AOA) and AOAAM. The AOA is accredited by the ACCME to provide continuing medical education for physicians.

      Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

      Davida Schiff, MD

      MassGeneral for Children

      Dr. Schiff is a general academic pediatrician and health services researcher focused on understanding how substance use in pregnant and parenting women impacts the health of children and families. She is the Medical Director of the HOPE Clinic (Harnessing support for Opioid and substance use disorder in Pregnancy and Early childhood) at Massachusetts General Hospital, a multidisciplinary program caring for women and families with substance use disorder from the time of conception through the first two years postpartum.

      Dr. Schiff completed her undergraduate training at Columbia University, medical training at the Boston University School of Medicine, pediatrics residency in the Boston Combined Residency Program at Boston Medical Center and Boston Children’s Hospital, general pediatrics research fellowship at Boston Medical Center, and master’s program in health services research from the Boston University School of Public Health. Her research is focused on improving care for families affected by substance use and her past scholarship has been published in the New England Journal of Medicine, JAMA, Pediatrics, Academic Pediatrics, Journal of Substance Abuse and Treatment, and Substance Abuse, among other journals. She is an Assistant Professor of pediatrics at Harvard Medical School.

      Julie Kmiec, DO, FAOAAM (Moderator)

      AOAAM Past President

      Julie Kmiec, DO, graduated from Western University of Health Sciences College of Osteopathic Medicine of the Pacific.  She completed her general psychiatry residency training and addiction psychiatry fellowship at Western Psychiatric Institute and Clinic (WPIC) in Pittsburgh, PA.  She is currently an Assistant Professor of Psychiatry at the University of Pittsburgh School of Medicine.  She is board certified in general and addiction psychiatry.  Dr. Kmiec is the Medical Director of the Ambulatory Detoxification Program, Bridge Clinic, and is the founding medical director of the Narcotic Addiction Treatment Program’s Buprenorphine Clinic at WPIC.  Her clinical interests include treatment of drug and alcohol withdrawal, prevention of overdose, and pharmacotherapy for the treatment of addictions.  Dr. Kmiec’s research involves training healthcare professionals on the implementation of medications for opioid use disorder.  She is the President of the American Osteopathic Academy of Addiction Medicine.